skip to content National Cancer Institute U.S. National Institutes of Health www.cancer.gov
Division of Cancer Prevention logo
Home Site Map Contact DCP
Skip to subnavigation.
Programs & Resources
skip sub-navigation, go to content.

Prostate and Urologic Cancer Research Group

Programs and Projects

Prostate Cancer Clinical Trials - Johns Hopkins University
Agent: Celecoxib
Contact: Michael Carducci, M.D.
DCP Program Director: Howard Parnes, M.D.

The purpose of this study is to evaluate the potential of Celecoxib as a chemopreventive agent for prostate cancer. Men with a diagnosis of prostate cancer who are considering surgical removal of the prostate gland (prostatectomy) may be eligible to participate in this study. Those taking part in the study will receive either Celecoxib or no agent (control group) for several weeks immediately before prostate surgery. The study is now closed to accrual.

[This is a phase 2 randomized double-blind placebo controlled trial of the selective COX 2 inhibitor (Celecoxib) administered for 4-6 weeks in the presurgical period prior to prostatectomy in men with localized prostate cancer. The primary endpoint is modulation of prostaglandins in prostatic epithelium (normal, HGPIN and cancer).]